In western countries, universal screening is routinely performed to detect MMR‐D CRCs.37, 38 When the tumor is MMR‐P, the pathogenic exonuclease domain mutations in the POLE gene are worth investigating because tumors with POLE proofreading deficiency are MMR‐P.1, 27 Accordingly, searching for pathogenic mutations at recurrent hot spots may be clinically practical. This evidence concerns the gene POLE and neoplasm.